Clinigen Group plc announced it has signed a distribution agreement, with Deciphera Pharmaceuticals for the supply and distribution of QINLOCK® into multiple countries across the globe. QINLOCK® was approved by the European Medicines Agency in November 2021 for the treatment of adult patients with advanced gastrointestinal stromal tumor who have received prior treatment with three or more kinase inhibitors, including imatinib. Under the agreement, Clinigen will supply QINLOCK® into multiple countries where it is not yet commercially available.

Clinigen will act as the main point of contact for healthcare professionals wanting to access QINLOCK®, managing all elements of the process including order and enquiry management, regulatory compliance, and logistics.